reports
ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthca...
ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, beginning at approximately 3:00 p.m. (Pacific Standard Time) in San Francisco, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting . The audio-only webcast replay ...
ResMed Inc: 2 directors
Two Directors at ResMed Inc sold 2,075 shares at 230.990USD. The significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
ResMed Announces Participation in the UBS Global Healthcare Conference
ResMed Announces Participation in the UBS Global Healthcare Conference SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at approximately 3:30 p.m. (Pacific Standard Time) at the Terranea Resort Hotel in Rancho Palos Verdes, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visit...
ResMed to Report First Quarter Fiscal 2025 Earnings on October 24, 202...
ResMed to Report First Quarter Fiscal 2025 Earnings on October 24, 2024 SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2025 on Thursday, October 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Location: Date: Thursday, October 24, 2024 Ti...
ResMed Unveils 2030 Strategy to Drive Growth, Profitability, and Share...
ResMed Unveils 2030 Strategy to Drive Growth, Profitability, and Shareholder Returns 2030 ambition to help more than 500 million people worldwide achieve their full health potentialShowcases integration of intelligent products and solutions within the ResMed ecosystem, designed to deliver a better experience, lower costs, and enhanced outcomes for patients and providersIntroduces updated five-year financial outlook NEW YORK and SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today unveiled its 2030 Strategy to drive growth, profitability, and shareholder ...
UPDATE -- ResMed Unveils New Collection of Digital and Personalized So...
UPDATE -- ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health ResMed makes it easier for people to manage their sleep health and stay on (continuous positive airway pressure) CPAP treatment by integrating its leading myAir™ consumer app with Apple and Android smartwatches. Introduces a Generative AI-enabled sleep health assistant to guide people on their journey to better sleep and new travel gear to help people stay on CPAP treatment while traveling. SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- (NYSE: RMD, ASX: RMD), the world’s leadin...
UPDATE -- ResMed Enhances CPAP Therapy with its First Fabric Mask, Des...
UPDATE -- ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to Make it Easier for People to Embrace Their Treatment and Improve Overall Sleep Health The new AirTouch™ N30i tube-up nasal mask for CPAP combines softness, breathability, and a high-performance, durable seal to provide exceptional comfort SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- (NYSE: RMD, ASX: RMD), the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a ResMed first in CPAP (continuous positive airway pressure) mask innovation with ...
ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to M...
ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to Make it Easier for People to Embrace Their Treatment and Improve Overall Sleep Health The new AirTouch™ N30i tube-up nasal mask for CPAP combines softness, breathability, and a high-performance, durable seal to provide exceptional comfort SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- (NYSE: RMD, ASX: RMD), the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a ResMed first in CPAP (continuous positive airway pressure) mask innovation with the launch...
ResMed Unveils New Collection of Digital and Personalized Solutions de...
ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health ResMed makes it easier for people to manage their sleep health and stay on (continuous positive airway pressure) CPAP treatment by integrating its leading myAir™ consumer app with Apple and Android smartwatches. Introduces a Generative AI-enabled sleep health assistant to guide people on their journey to better sleep and new travel gear to help people stay on CPAP treatment while traveling. SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- (NYSE: RMD, ASX: RMD), the world’s leading health t...
ResMed to Host Its 2024 Investor Day on September 30, 2024, at the New...
ResMed to Host Its 2024 Investor Day on September 30, 2024, at the New York Stock Exchange Learn more about ResMed’s 2030 strategy to accelerate growthJoin in person or via virtual webcast SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) will host an investor day on Monday, September 30, 2024, beginning at approximately 1:00 p.m. (Eastern Daylight Time). As previously announced, the event will be held at the New York Stock Exchange in New York City and simultaneously webcast online. More information about this event, including access to the live webcast...
Vaping Expected to Increase COPD Health and Economic Burden by 2050
Vaping Expected to Increase COPD Health and Economic Burden by 2050 New ResMed-supported research presented at ERS 2024 projects future Chronic Obstructive Pulmonary Disease (COPD) burden in Western Europe, accounting for increased air pollution, tobacco smoking, and vaping, with Non-Invasive Ventilation (NIV) enhancing survival rates. 88.7 million new COPD hospitalizations projected across Western Europe between 2019 - 2050Vaping projected to incur almost €30 billion additional direct and indirect costs by 2050€4.9 trillion projected cumulative cost to support COPD lung conditions by 2050...
ResMed Announces Participation in the Morgan Stanley 22nd Annual Globa...
ResMed Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024, beginning at approximately 10:00 a.m. (Eastern Daylight Time) at the New York Marriott Marquis in New York, NY. More information about this event, including access to the live, audi...
ResMed Expands its Board of Directors and Appoints Healthcare Executiv...
ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its Board DelOrefice is the Chief Financial Officer at BD, one of the largest global MedTech companies in the worldBoard appointment brings over 30 years of strategic and operational finance expertise SAN DIEGO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it has expanded the size of its board of directors to 11 and has elected Christopher DelOrefice to the board, effective immediately. Mr. DelOrefice was appointed during ResMed’...
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 20...
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2024 Year-over-year revenue grows 9%, operating profit up 38%, non-GAAP operating profit up 30%Operating cash flow of $440 millionQuarterly dividend increases 10% to $0.53 per shareCompany to host an Investor Day on September 30, 2024 Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended June 30, 2024. Fourth Quarter 2024 HighlightsAll comparisons are to the prio...
ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024
ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024 SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2024 on Thursday, August 1, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Location: Date: ...
PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for P...
PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia ResMed studies presented at SLEEP 2024 also revealed a 17% prevalence of insomnia among adults in North America, Latin America, and the Caribbean, and a higher rate of depression in women with OSA SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading medical researchers from around the world, ResMed (NYSE: RMD, ASX: RMD) presented 13 new clinical studies at SLEEP 2024, the annual joint meeting of the American Academy of Sleep Medicine and th...
Developed in Collaboration with Leading Scientists, New ResMed-Support...
Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy Among 26 ResMed-supported abstracts, these were the highlights: New findings show positive airway pressure (PAP) therapy reduced risks of death and hospitalization for patients with obstructive sleep apnea (OSA)Prevalence of OSA in the United States expected to increase 26.7% in men and women aged 30 –70Real-world trends of glucagon-like peptide-1 (GLP-1) receptor agonist and PAP therapy use show patient...
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence o...
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- When: May 17–22, 2024Where: San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101 Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101 Research: 26 ResMed-supported abstracts will be presented at ATS. Full list below. Highlights: Treatment of Sleep-Disordered Breathing with Adaptive Servo-Ventilat...
ResMed Announces Participation in the RBCCM Global Healthcare Conferen...
ResMed Announces Participation in the RBCCM Global Healthcare Conference SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Dr. Carlos Nunez, Chief Medical Officer, and Amy Wakeham, Chief Investor Relations Officer, will participate in a fireside chat at the 2024 RBCCM Global Healthcare Conference on Tuesday, May 14, 2024, beginning at approximately 4:05 p.m. (Eastern Daylight Time) at the InterContinental New York Barclay, in New York, NY. More information about this event, including access to the live, audio-only webcast, may be accessed by visitin...
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 202...
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024 Year-over-year revenue grows 7%, operating profit up 25%, non-GAAP operating profit up 23%Operating cash flows of $402 million Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2024. Third Quarter 2024 HighlightsAll comparisons are to the prior year period Revenue increased by 7% to $1.2 billion; up 7% on a constant currency ba...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.